New Lantus(R) ClikSTAR(TM) eco-friendly insulin pen now available in Canada
- Easy-to-use and reliable device helps patients achieve their treatment goals -
LAVAL, QC,
"With the introduction of Lantus ClikSTAR, we offer a new device for patients with type 1 and type 2 diabetes," said Dr. Laurent-Didier Jacobs, Vice-President, Medical Affairs at sanofi-aventis
The Lantus ClikSTAR pen, designed in partnership with nearly 2,000 patients and 500 nurses, is the result of over four years of intensive development and testing aimed at addressing patients' needs. The reusable pen has all the benefits of the pre-filled Lantus SoloSTAR and Apidra SoloSTAR delivery device, including a low injection force, a dial and dose setting that allows patients to administer doses from one to 80 units in a single injection, numbering that is both large and clear that lessens the possibility of injection error, and a dial back safety feature to correct dose selection errors.
"It's an added bonus that the Lantus ClikSTAR was developed with patients' needs in mind," said Stacey Horodezny, a diabetes educator based at the Trillium Health Centre in Mississauga, Ontario.
"For patients, ease of use, flexibility and comfort are what matter most," she added. "For us, as nurse educators, these features are also important because they allow us to spend more time on all the other aspects of insulin and diabetes management."
In addition to
Diabetes in
Diabetes is a chronic condition in which the body does not produce or properly use insulin - the hormone needed to convert glucose (sugar) into energy. In
About Lantus and Apidra
Lantus is a novel recombinant human insulin analog approved for once-daily administration in the treatment of patients over the age of 17 with type 1 or type 2 diabetes who require basal (long-acting) insulin for the control of hyperglycemia (abnormally high blood sugar). Lantus is also indicated in the treatment of pediatric patients with type 1 diabetes.
Apidra is a rapid-acting recombinant human insulin analog that offers patients (both type 1 and type 2) mealtime dosing flexibility. The injection can be administered up to 15 minutes before or within 20 minutes after starting a meal.
Hypoglycemia (low blood glucose) is the most common adverse event associated with Lantus and Apidra. Other adverse events commonly associated with Lantus and Apidra include allergic reactions, injection site reaction and lipohypertrophy (small fat deposits at injection site).
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Backed by a world-class R&D organization, the company is developing leading positions in several therapeutic areas: cardiology, thrombosis, oncology, metabolic disorders, the central nervous system, internal medicine and vaccines.
Sanofi-aventis is represented in
For further information: or to speak with an endocrinologist, please contact: Laine Jaremey, MS&L, (416) 847-1321, [email protected]; Claudette Baltayan, sanofi-aventis Canada, (514) 856-8748, [email protected]
Share this article